1 |
Botox (OnabotulinumtoxinA) [package insert]. Irvine (Botox) [package insert]. Irvine: Allergan; 2011.
|
2 |
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
DOI
|
3 |
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30: 804-14.
DOI
|
4 |
Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta-analysis of randomized controlled trials. Brain Behav 2019;9:e01409.
|
5 |
Calvani F, Santini S, Bartoletti E, Alhadeff A. Personal technique of microinfiltration with botulin toxin: the SINB technique (superficial injection needling botulinum). Plast Surg (Oakv) 2019;27:156-61.
DOI
|
6 |
Carruthers A, Carruthers J. History of botulinum toxin for medical and aesthetic use. In: Cohen JL, Ozog DM, Porto DA, editors. Botulinum toxins: cosmetic and clinical applications. Hoboken: John Wiley & Sons Inc.; 2017. p. 1-12.
|
7 |
Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949;109:10-24.
DOI
|
8 |
Lipham WJ. A brief history of the clinical applications of botulinum toxin. In: Lipham WJ, editor. Cosmetic and clinical applications of botulinum toxin. Thorofare: SLACK; 2004. p. 1-3.
|
9 |
Brooks VB. The action of botulinum toxin on motor-nerve filaments. J Physiol 1954;123:501-15.
DOI
|
10 |
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044-9.
DOI
|
11 |
Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum: a exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
DOI
|
12 |
Ahn KY, Park MY, Park DH, Han DG. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 2000;105:778-84.
DOI
|
13 |
Kane M, Donofrio L, Ascher B, Hexsel D, Monheit G, Rzany B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010;9(1 Suppl):s7-22.
|
14 |
Ahmed NY, Knowles R, Dehorter N. New insights into cholinergic neuron diversity. Front Mol Neurosci 2019;12:204.
DOI
|
15 |
Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol Rev 2012;92:1189-234.
DOI
|
16 |
Pijning AE, Chiu J, Yeo RX, Wong JW, Hogg PJ. Identification of allosteric disulfides from labile bonds in X-ray structures. R Soc Open Sci 2018;5:171058.
DOI
|
17 |
Shone CC. Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson DH, editor. Natural toxicants in foods. Chichester: Ellis Harwood Ltd; 1986. p. 11-57.
|
18 |
Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.
DOI
|
19 |
Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427-53.
DOI
|
20 |
Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-44.
DOI
|
21 |
Pearce LB, First ER, MacCallum RD, Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 1997;35:1373-412.
DOI
|
22 |
Brin MF, Dressler D, Aoki KR. Pharmacology of botulinum toxin therapy. In: Brin MF, Comella C, Jankovic J, editors. Dystonia: etiology, clinical feature, and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 93-108.
|
23 |
Jung GS, Cho IK, Sung HM. Submandibular gland reduction using botulinum toxin type A for a smooth jawline. Plast Reconstr Surg Glob Open 2019;7:e2192.
DOI
|
24 |
Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29:477-83.
DOI
|
25 |
Park MY, Ahn KY. The comparison of long-term effect of botox(R) injection on lower face contouring after single injection and long-term repeated injections by standardized photograph analysis. J Korean Soc Plast Reconstr Surg 2009;36:654-9.
|
26 |
Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis. Med Sci Monit 2019;25:2950-8.
DOI
|
27 |
Park MY, Porto DA, Ahn KY. Contouring of the lower face and the lower leg and calf. In: Cohen JL, Ozog DM, Porto DA, editors. Botulinum toxins: cosmetic and clinical applications. Hoboken: John Wiley & Sons Inc.; 2017. p. 177-90.
|
28 |
Lee JH, Lee KY, Kim JY, Son WH, Jeong JH, Gil Jeong Y, et al. Botulinum toxin injection-site selection for a smooth shoulder line: an anatomical study. Biomed Res Int 2017;2017:3092720.
DOI
|
29 |
Al-Fouzan AF, Mokeem LS, Al-Saqat RT, Alfalah MA, Alharbi MA, Al-Samary AE. Botulinum toxin for the treatment of Gummv smile. J Contemp Dent Pract 2017;18:474-8.
DOI
|
30 |
Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999;103:645-52.
DOI
|
31 |
Kandhari R, Kaur I, Sharma D. Mesococktails and mesoproducts in aesthetic dermatology. Dermatol Ther 2020;33:e14218.
DOI
|
32 |
Childers MK. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil 2004;83(10 Suppl):S38-44.
DOI
|
33 |
Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013;28:1775-83.
DOI
|
34 |
Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009;40:374-80.
DOI
|
35 |
Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 2011;58:159-67.
DOI
|
36 |
Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-8.
DOI
|
37 |
Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;9: 31-9.
DOI
|
38 |
Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 2011;31:15650-9.
DOI
|
39 |
Aoki KR. Botulinum toxin: a successful therapeutic protein. Curr Med Chem 2004;11:3085-92.
DOI
|
40 |
Francisco GE, Tan H, Green M. Do botulinum toxins have a role in the management of neuropathic pain? A focused review. Am J Phys Med Rehabil 2012;91:899-909.
DOI
|
41 |
Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a doubleblind, randomized trial. Neurology 2005;65:765-7.
DOI
|
42 |
Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43(2 Pt 1):249-59.
DOI
|
43 |
Kim SH, Lee SJ, Kim HJ, Lee JH, Jeong HS, Suh IS. Aging-related changes in the mid-face skin elasticity in East Asian women. Arch Craniofac Surg 2019;20:158-63.
DOI
|